How will the newer JCEM guidelines on primary aldosteronism (PA) impact your management and screening of PA?

I believe you are going to see more screening for PA and more assistance needed by healthcare providers on how to interpret the results. I also believe that perhaps this may lead to more use of steroidal MRA, which is a great thing for many patients having trouble with control of low-renin HTN.